ABL DiagnosticsXPAR:ABLD +0.76%51 Shareholder Yield % is 6.75% as of Dec. 2025, which is 788% above its 10-year median of 0.76. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 654 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 83.49% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, ABL Diagnostics's Shareholder Yield % was 6.75%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
ABL Diagnostics Shareholder Yield % Related Terms
ABL Diagnostics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Shareholder Yield % Comparison
For the Health Information Services subindustry, ABL Diagnostics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Shareholder Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
ABL Diagnostics (XPAR:ABLD) has a Shareholder Yield % of 6.75% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ABL Diagnostics and its competitors. This is 788% above median its historical median of 0.76. According to the industry distribution chart, ABL Diagnostics ranks #108 out of 654 companies in the Healthcare Providers & Services industry, placing it in the top 16.5%.
Is ABL Diagnostics' Shareholder Yield % too high?
ABL Diagnostics' current Shareholder Yield % of 6.75% is 788% above median its 10-year median of 0.76. The Healthcare Providers & Services industry median Shareholder Yield % is 0.08. ABL Diagnostics' value of 6.75% is 8900% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #108 out of 654 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Shareholder Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #108 out of 654 companies for Shareholder Yield %. This places ABL Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.08. ABL Diagnostics' value of 6.75% is 8900% above this benchmark. While the company's 10-year median is 0.76 vs. the industry median of 0.08, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Healthcare Providers & Services company?
The median Shareholder Yield % among Healthcare Providers & Services companies is 0.08, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Shareholder Yield % of 6.75% is 8900% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Shareholder Yield % is 0.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Shareholder Yield % is 6.75%, which is 788% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Shareholder Yield % is 6.75%, which is 788% above median its 10-year median of 0.76 and 8900% above the Healthcare Providers & Services industry median of 0.08. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Shareholder Yield % is 6.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Shareholder Yield %: 6.75% (788% above median its 10-year median of 0.76)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 8900% above the Healthcare Providers & Services median (#108 of 654)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
